Enoxaparin in ACS

More documents

Recommendations

Info

o DefinitionsAgendao Is UFH w/o disadvantageso High risk combination of anticoagulants inthe management of ACSo SKo Fibrinolyticso IIb/IIIa Inhibitorso When evidence meets real world practiceEnoxaparin incombination withGPIIb/IIIa inhibitors
Enoxaparin and GP IIb/IIIa inhibitors inUA/NSTEMI‣ ACUTE II: second Antithrombotic Combination UsingTirofiban and EnoxaparinCohen M et al. Am Heart J 2002‣ INTERACT: Integrilin and EnoxaparinRandomizedAssessment of Acute Coronary Syndromes TreatmentGoodman S et al. Circulation 2003‣ SYNERGY: SuperiorYield of the New strategy of Enoxaparin,Revascularization & GlYcoprotein IIb/IIIa InhibitorsACUTE II: TIMI Bleeding EventsTirofiban + UFH (n=210)Tirofiban + enoxaparin (n=315)TIMI-major0.31.0P=NSTIMI-minor2.54.3P=NSTIMI-“lossno site”3.54.8P=NS0 1 2 3 4 5Patients (%)
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5 and 6: Superiority ofEnoxaparin over UFHEv
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13 and 14: New Data from ExTRACT-TIMI 251YEAR
Page 15 and 16: Net Clinical BenefitDeath/MI/Disabl
Page 17: Summary-23. Net clinical benefit si
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?